Mutations in RAS genes are common in patients with colorectal cancer (CRC), occurring in nearly 40% of all CRC cases, and result in resistance to treatment with epidermal growth factor receptor (EGFR) monoclonal antibodies [1,2]. Here, EGFR is linked to colorectal carcinoma.